Coherus Oncology (CHRS) Receivables - Net (2016 - 2025)
Coherus Oncology (CHRS) has disclosed Receivables - Net for 12 consecutive years, with $17.8 million as the latest value for Q4 2025.
- Quarterly Receivables - Net fell 84.0% to $17.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.8 million through Dec 2025, down 84.0% year-over-year, with the annual reading at $17.8 million for FY2025, 84.0% down from the prior year.
- Receivables - Net hit $17.8 million in Q4 2025 for Coherus Oncology, up from $9.2 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $260.5 million in Q4 2023 to a low of $5.1 million in Q2 2025.
- Historically, Receivables - Net has averaged $124.7 million across 5 years, with a median of $120.0 million in 2021.
- Biggest five-year swings in Receivables - Net: surged 148.33% in 2024 and later tumbled 97.08% in 2025.
- Year by year, Receivables - Net stood at $123.0 million in 2021, then dropped by 10.61% to $110.0 million in 2022, then surged by 136.92% to $260.5 million in 2023, then crashed by 57.27% to $111.3 million in 2024, then tumbled by 84.0% to $17.8 million in 2025.
- Business Quant data shows Receivables - Net for CHRS at $17.8 million in Q4 2025, $9.2 million in Q3 2025, and $5.1 million in Q2 2025.